In the past several decades, various advances have revolutionized the prognosis and outcome of many rheumatic diseases. Such advances include the concepts of tight control, treat to target, the development of biologics and targeted therapies. This combination of approaches and the availability of new and much more effective therapies has changed the expectations of physicians and patients alike.
However, one of the challenges that has appeared among these advances is drug survival. For reasons such as adverse events, primary and secondary failures and costs, drug survival in biologics and new small target specific therapies have proven to be much shorter than expected. Since many patients with chronic rheumatic diseases run out of treatment options after a few years of therapy, drug survival should be further studied in order to enhance the success of treatment of rheumatic diseases.
Here, we invite authors to submit original research and review articles on drug survival in rheumatic diseases during the era of biologic use. We are interested in articles that explore the role of drug survival in the treatment, and it’s possible consequences.
Potential topics include, but are not limited to:
? Biologics and small molecules specific target therapies survival in real world
? Risk factors for biologics and small molecules discontinuations
? Adherence to treatment
? Treatment strategies to improve drug survival
? Immunogenicity of new treatments
? Role of biosimilars in drug survival
In the past several decades, various advances have revolutionized the prognosis and outcome of many rheumatic diseases. Such advances include the concepts of tight control, treat to target, the development of biologics and targeted therapies. This combination of approaches and the availability of new and much more effective therapies has changed the expectations of physicians and patients alike.
However, one of the challenges that has appeared among these advances is drug survival. For reasons such as adverse events, primary and secondary failures and costs, drug survival in biologics and new small target specific therapies have proven to be much shorter than expected. Since many patients with chronic rheumatic diseases run out of treatment options after a few years of therapy, drug survival should be further studied in order to enhance the success of treatment of rheumatic diseases.
Here, we invite authors to submit original research and review articles on drug survival in rheumatic diseases during the era of biologic use. We are interested in articles that explore the role of drug survival in the treatment, and it’s possible consequences.
Potential topics include, but are not limited to:
? Biologics and small molecules specific target therapies survival in real world
? Risk factors for biologics and small molecules discontinuations
? Adherence to treatment
? Treatment strategies to improve drug survival
? Immunogenicity of new treatments
? Role of biosimilars in drug survival
